Cargando…

P-009: IDENTIFYING BARRIERS FOR PATIENTS WITH SICKLE CELL DISEASE TO ACCESS TREATMENT WITH HYDROXYUREA – A QUALITATIVE ANALYSIS OF THE SUPPLY CHAIN IN GHANA

Detalles Bibliográficos
Autores principales:	S., GRAVEN, K., MARFO, A., KARIM, A., BISCHOF, A., GEISSLER
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Poster Presentations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9426814/ http://dx.doi.org/10.1097/01.HS9.0000872940.76494.9b

Ejemplares similares

S129: IMPLEMENTATION OF HYDROXYUREA THERAPY FOR SICKLE CELL DISEASE ON A LARGE SCALE IN GHANA
por: Ohene-Frempong, K, et al.
Publicado: (2022)

Barriers and Facilitators of Availability of Hydroxyurea for Sickle Cell Disease in Tanzania; A Qualitative Study of Pharmaceutical Manufacturers, Importers, and Regulators
por: Mlyuka, Hamu J., et al.
Publicado: (2022)

Hydroxyurea Treatment for Sickle Cell Disease
por: Steinberg, Martin H.
Publicado: (2002)

P1489: MANAGEMENT OF SICKLE CELL DISEASE WITH HYDROXYUREA: A SYSTEMATIC REVIEW FROM LOW- AND MIDDLE-INCOME COUNTRIES
por: Paintsil, V., et al.
Publicado: (2022)

P-007: HYDROXYUREA FOR THE MANAGEMENT OF SICKLE CELL DISEASE IN LOW- AND MIDDLE-INCOME COUNTRIES: A SYSTEMATIC REVIEW (2000–2022)
por: L., TSHILOLO, et al.
Publicado: (2022)

Promoting access of hydroxyurea to sickle cell disease individuals: Time to make it an essential medicine
por: Kilonzi, Manase, et al.
Publicado: (2022)

Hydroxyurea and sickle cell anemia: effect on quality of life
por: Ballas, Samir K, et al.
Publicado: (2006)

Barriers to Therapeutic Use of Hydroxyurea for Sickle Cell Disease in Nigeria: A Cross-Sectional Survey
por: Okocha, Emmanuel Chide, et al.
Publicado: (2022)

Effective control of sickle cell disease with hydroxyurea therapy
por: Singh, Harminder, et al.
Publicado: (2010)

The influence of hydroxyurea on oxidative stress in sickle cell anemia
por: Torres, Lidiane de Souza, et al.
Publicado: (2012)

Evaluation of hydroxyurea genotoxicity in patients with sickle cell disease
por: de Oliveira, Emanuel Almeida Moreira, et al.
Publicado: (2019)

Outcomes of Hydroxyurea Accessed via Various Means and Barriers Affecting Its Usage Among Children with Sickle Cell Anaemia in North-Western Tanzania
por: Ambrose, Emmanuela E, et al.
Publicado: (2023)

ENHANCE—(Electronic Hydroxyurea Adherence): A Protocol to Increase Hydroxyurea Adherence in Patients with Sickle Cell Disease
por: Creary, Susan, et al.
Publicado: (2016)

Improving routine outpatient monitoring for patients with sickle-cell disease on hydroxyurea
por: Ward, Joel, et al.
Publicado: (2018)

The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea
por: da Silva, Luiz Bernardino Lima, et al.
Publicado: (2012)

Comment on "The influence of hydroxyurea on oxidative stress in sickle cell anemia"
por: van Beers, Eduard Johannes, et al.
Publicado: (2012)

Emerging Science of Hydroxyurea Therapy for Pediatric Sickle Cell Disease
por: Green, Nancy S., et al.
Publicado: (2013)

Hydroxyurea: Clinical and Hematological Effects in Patients With Sickle Cell Anemia
por: Keikhaei, Bijan, et al.
Publicado: (2016)

Concurrent use of hydroxyurea and deferasirox in Californians with sickle cell disease
por: Wong, Trisha E., et al.
Publicado: (2021)

Mathematical Modeling of Hydroxyurea Therapy in Individuals with Sickle Cell Disease
por: Pandey, Akancha, et al.
Publicado: (2022)

Hydroxyurea treatment for adult sickle cell anemia patients in Kinshasa
por: Kabuyi, Paul Lumbala, et al.
Publicado: (2023)

Intensive hydroxyurea dosing in very young children with sickle cell anemia
por: Wang, Winfred C., et al.
Publicado: (2023)

Comment on "The burden and quality of life of caregivers of sickle cell anemia patients taking hydroxyurea versus those not taking hydroxyurea"
por: Souza, José Carlos, et al.
Publicado: (2012)

Response to Hydroxyurea in a Patient With Sickle Cell Hepatopathy: A Case Report
por: Safhi, Maha A, et al.
Publicado: (2021)

Hydroxyurea Use and Hospitalization Trends in a Comprehensive Pediatric Sickle Cell Program
por: Nottage, Kerri A., et al.
Publicado: (2013)

Hydroxyurea-Induced miRNA Expression in Sickle Cell Disease Patients in Africa
por: Mnika, Khuthala, et al.
Publicado: (2019)

Genetic and biochemical markers of hydroxyurea therapeutic response in sickle cell anemia
por: Silva, Danilo Grunig Humberto, et al.
Publicado: (2013)

Pure Erythroid Leukemia in a Sickle Cell Patient Treated with Hydroxyurea
por: Yadav, Dhiraj Kumar, et al.
Publicado: (2020)

Optimizing Hydroxyurea Treatment for Sickle Cell Disease Patients: The Pharmacokinetic Approach
por: Nazon, Charlotte, et al.
Publicado: (2019)

Menopause in Brazilian women with sickle cell anemia with and without hydroxyurea therapy
por: Queiroz, Ana Mach, et al.
Publicado: (2021)

A systematic review on hydroxyurea therapy for sickle cell disease in India
por: Pandey, Apoorva, et al.
Publicado: (2022)

Utilization of Hydroxyurea Among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia
por: Gohal, Gassem A, et al.
Publicado: (2022)

Whole Exome Sequencing Identifies Novel Genes for Fetal Hemoglobin Response to Hydroxyurea in Children with Sickle Cell Anemia
por: Sheehan, Vivien A., et al.
Publicado: (2014)

Side effects of hydroxyurea in patients with Thalassemia major and thalassemia intermedia and sickle cell anemia
por: Ghasemi, A, et al.
Publicado: (2014)

The impact of COVID-19 on antimalarial supply chains in Ghana
por: Hampshire, Kate, et al.
Publicado: (2021)

Influence of βS-Globin Haplotypes and Hydroxyurea on Arginase I Levels in Sickle Cell Disease
por: Moreira, J. A., et al.
Publicado: (2016)

Candidate Sequence Variants and Fetal Hemoglobin in Children with Sickle Cell Disease Treated with Hydroxyurea
por: Green, Nancy S., et al.
Publicado: (2013)

Preliminary evidence that hydroxyurea is associated with attenuated peripheral sensitization in adults with sickle cell disease
por: Letzen, Janelle E., et al.
Publicado: (2019)

Barriers to hydroxyurea use from the perspectives of providers, individuals with sickle cell disease, and families: Report from a U.S. regional collaborative
por: Treadwell, Marsha J., et al.
Publicado: (2022)

Level of utilization and provider-related barriers to the use of hydroxyurea in the treatment of sickle cell disease patients in Jos, North-Central Nigeria
por: Ofakunrin, Akinyemi OD, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5jicphvkqfee2jlls66hv4a4q5